Page 2 - Between Mar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. Body weight reduction at week 72 was significantly greater with tirzepatide versus placebo. 2. Hemoglobin A1c was significantly reduced with tirzepatide versus placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity is a chronic disease that is expected to affect nearly 2 billion people by 2035. Although weight reduction is a key component of

1. 5-year ipsilateral breast tumor relapse rates for test group 1 were non-inferior to the control group. However, noninferiority was not shown with test group 2 versus control. 2. Test group 2 was found to have a higher rate of moderate or marked breast induration compared to the control group and test group 1. Evidence

1. All-cause and cardiovascular mortality rates were greater in the 24h systolic blood pressure group than clinic systolic blood pressure group. 2. Night-time systolic blood pressure was most predictive of all-cause and cardiovascular mortality. Evidence Rating Level: 2 (Good) Study Rundown: Hypertension is often known as one of the leading causes of cardiovascular morbidity and

1. All-cause and cardiovascular mortality rates were greater in the 24h systolic blood pressure group than clinic systolic blood pressure group. 2. Night-time systolic blood pressure was most predictive of all-cause and cardiovascular mortality. Evidence Rating Level: 2 (Good) Study Rundown: Hypertension is often known as one of the leading causes of cardiovascular morbidity and mortality. While

1. Adverse pregnancy outcomes were less frequent among patients in the sulfadoxine-pyrimethamine group. 2. Differences in adverse pregnancy outcomes were mainly driven by an increased incidence of low birth weight and small for gestational age pregnancies. Evidence Rating Level: 1 (Excellent) Study Rundown: Plasmodium falciparum malaria infection can have adverse maternal and fetal outcomes. Studies